Sola Diagnostics

Epigenetic tests for precision prevention of women's cancers.

illustration of womb cancer

Sola Diagnostics was founded by Professor Martin Widschwendter (UCL EGA Institute for Women’s Health and University of Innsbruck), in 2022 to develop epigenetic tests for precision prevention of women’s cancers. 

To date, Sola have launched the WID®-easy test, a diagnostic test for womb cancer, which prevents unnecessary invasive diagnostic procedures.

The Sola Diagnostics journey so far: 

  • 2022: Sola was founded 
  • 2025: WID-Easy Test launched in Europe

Team

Professor Martin Widschendter

Founder and Executive Chair

Professor Widschwendter’s research focuses on cancers of the breast, uterus, cervix, and ovaries, with his long-term goal being the elimination of women-specific cancers.

Caitriona O'Rourke

Dr. Caitriona O'Rourke (Away from office)

Senior Business Manager

Dr O’Rourke joined us in 2018, having worked as a research associate within UCL on several diverse life science / pharmaceutical research projects covering the areas of tissue engineering, drug delivery, regenerative medicine, biomaterials and stem cell biology.

Caitriona holds a PhD in tissue engineering from the Open University and a MSc in neuropharmacology from the National University of Galway, Ireland.